Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination with pembrolizumab in patients with advanced solid tumors
Phase 1
Recruiting
- Conditions
- Selected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2024-514746-36-00
- Lead Sponsor
- Oncomatryx Biopharma S.L.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the mechanism of OMTX705 ADC in targeting FAP-expressing stroma and tumor cells in carcinomas and sarcomas?
How does OMTX705 plus pembrolizumab compare to standard therapies in FAP-positive advanced solid tumors?
Which biomarkers predict response to OMTX705 in FAP-expressing carcinomas and sarcomas?
What are the safety profiles and toxicity management strategies for OMTX705 as a single agent and in combination with pembrolizumab?
What are the current anti-FAP antibody-drug conjugates in development for advanced solid tumors, and how does OMTX705 compare?